Curaleaf Launches Free CPD-Accredited Medical Cannabis Education Platform for UK Healthcare Professionals
Curaleaf International, one of the world’s leading medical cannabis companies, has launched a comprehensive CPD-accredited Education Platform designed to improve healthcare professionals’ understanding of medical cannabis across the United Kingdom. The initiative aims to address a longstanding educational gap by providing clinicians with free access to evidence-based learning resources, helping them better understand the science, regulation, and clinical applications of cannabis-based medicines.
The online platform represents a significant step toward strengthening professional education in a field that has grown rapidly since medical cannabis became legal in the UK in 2018. While patient access to prescribed cannabis-based medicines has steadily increased over the past several years, medical education has struggled to keep pace, leaving many doctors uncertain about prescribing practices, clinical evidence, and regulatory requirements.
Curaleaf’s new educational initiative seeks to bridge that divide by offering structured learning pathways that combine scientific research, clinical guidance, and real-world patient data. Healthcare professionals who complete the modules receive Continuing Professional Development (CPD) accreditation, allowing them to expand their knowledge while fulfilling ongoing professional education requirements.
Addressing a Significant Knowledge Gap
Despite nearly eight years having passed since the legalization of specialist-prescribed medical cannabis in the UK, education on cannabis-based medicines remains limited within undergraduate medical curricula and postgraduate professional training.
A recent survey conducted by Curaleaf highlights the scale of the educational challenge facing UK healthcare professionals.
According to the findings, only 4% of general practitioners (GPs) reported receiving any formal education regarding medical cannabis during their professional training. Meanwhile, 81% described their understanding of medical cannabis as either limited or entirely absent.
The survey also revealed that 55% of respondents stated they would require a much stronger understanding of medical cannabis before feeling comfortable recommending it to patients.
These findings illustrate a broader issue within healthcare education. While medical cannabis has become an accepted treatment option for selected patients with specific conditions, many clinicians have not received sufficient instruction regarding:
- The endocannabinoid system
- Cannabis-derived medicines
- Clinical indications
- Evidence supporting treatment
- Patient eligibility
- Prescribing pathways
- Safety considerations
- Regulatory compliance
As patient awareness continues to grow, healthcare professionals increasingly encounter questions about medical cannabis during routine consultations. Without structured education, many clinicians lack the confidence needed to provide informed guidance.
Medical Cannabis Adoption Continues to Expand
Since legalization in 2018, access to medical cannabis has steadily increased throughout the United Kingdom.
Today, more than 60,000 UK patients receive medical cannabis through prescription for a variety of qualifying conditions under specialist supervision.
Patients commonly seek treatment for conditions including:
- Chronic pain
- Anxiety disorders
- Multiple sclerosis-related symptoms
- Epilepsy
- Treatment-resistant conditions
- Neurological disorders
- Sleep disturbances
- Certain palliative care indications
As patient demand continues to rise, clinicians across both primary and secondary care settings are becoming more interested in understanding where cannabis-based medicines may fit within modern treatment pathways.
However, despite increasing patient numbers and expanding clinical evidence, educational opportunities have remained relatively limited compared to other therapeutic areas.
Introducing the Curaleaf Education Platform
To help address these challenges, Curaleaf has developed the Curaleaf Education Platform, an online learning environment specifically designed for healthcare professionals.
The platform provides a structured educational framework covering every stage of medical cannabis knowledge—from foundational scientific concepts through advanced clinical practice.
Registration is completely free, allowing clinicians throughout the UK to access learning materials regardless of previous experience with medical cannabis.
Participants progress through multiple learning stages, beginning with introductory concepts before moving toward more advanced clinical applications.
Upon successful completion of each educational module, users receive CPD accreditation, supporting their continuing professional development while enhancing their clinical knowledge.
The learning system has been designed to accommodate busy healthcare professionals, enabling flexible online study at their own pace.
Structured Learning Pathway
The Education Platform organizes its curriculum into three primary educational pillars.
Foundations of Medical Cannabis
The introductory section focuses on the scientific principles that underpin cannabis-based medicines.
Healthcare professionals are introduced to:
- The biology of the endocannabinoid system
- Cannabinoid pharmacology
- Different cannabis compounds
- Mechanisms of therapeutic action
- Historical development of medical cannabis
- Current regulatory frameworks
- Safety fundamentals
This foundational knowledge provides clinicians with a scientific understanding before progressing into clinical decision-making.
Core Knowledge for Clinical Practice
The second learning pathway concentrates on practical clinical application.
Topics include:
- Patient assessment
- Treatment eligibility
- Prescribing considerations
- Dosing strategies
- Monitoring treatment outcomes
- Managing adverse effects
- Drug interactions
- Documentation requirements
- Clinical governance
- Regulatory compliance
These modules aim to equip healthcare professionals with practical knowledge that supports safe integration into clinical practice.
Specialist Conditions
The final educational pillar explores how medical cannabis may be used across various specialist therapeutic areas.
The curriculum reviews available clinical evidence surrounding multiple conditions while discussing:
- Existing treatment guidelines
- Evidence quality
- Clinical outcomes
- Patient selection
- Risk-benefit considerations
- Ongoing research
This specialist content enables clinicians to deepen their understanding of medical cannabis within specific areas of medicine.
Evidence-Based Educational Design
A distinguishing feature of the Curaleaf Education Platform is its emphasis on evidence-based medicine.
Rather than relying on anecdotal information or emerging trends, the educational content draws upon:
- Published scientific literature
- Clinical research
- Specialist expertise
- Regulatory guidance
- Real-world patient outcomes
The curriculum incorporates insights derived from the UK Medical Cannabis Registry, one of the world’s largest real-world databases dedicated to cannabis-based medical treatments.
Containing clinical information from more than 55,000 patients, the registry provides valuable evidence regarding treatment outcomes, prescribing trends, patient safety, and long-term effectiveness.
Real-world evidence has become increasingly important in modern medicine, complementing randomized clinical trials by offering insight into how therapies perform across broader patient populations under routine clinical conditions.
By incorporating registry findings into educational materials, Curaleaf seeks to ensure that clinicians receive information grounded in actual clinical experience as well as published research.
Improving Clinical Confidence
One of the primary goals of the platform is increasing clinician confidence.
Many healthcare professionals report uncertainty when patients ask about medical cannabis.
Questions commonly include:
- Could medical cannabis help my condition?
- Is it safe?
- Who qualifies?
- How is treatment monitored?
- Are there interactions with existing medications?
- What regulations apply?
Without formal education, clinicians may struggle to answer these questions confidently.
The Education Platform aims to reduce uncertainty by providing standardized, evidence-led educational resources that help healthcare professionals conduct informed discussions with patients.
Improved clinician knowledge may also support better shared decision-making, allowing patients to receive balanced information regarding both the potential benefits and limitations of cannabis-based medicines.
Supporting Responsible Integration
Curaleaf emphasizes that expanding education is essential for ensuring responsible adoption of medical cannabis within healthcare systems.
As with any emerging therapeutic field, clinician education plays an important role in maintaining patient safety and ensuring appropriate prescribing practices.
The platform therefore focuses not only on potential therapeutic applications but also on:
- Regulatory responsibilities
- Ethical prescribing
- Patient monitoring
- Contraindications
- Risk management
- Compliance with UK healthcare standards
By strengthening professional understanding, Curaleaf hopes to support consistent clinical practice while encouraging evidence-informed decision-making.
Research Director Highlights Educational Need
Commenting on the launch, Dr. Simon Erridge, Research Director at Curaleaf Clinic, said that many healthcare professionals are interested in learning about medical cannabis but lack access to formal education.
According to Dr. Erridge, he regularly speaks with general practitioners and consultants who wish to have informed conversations with patients regarding cannabis-based treatments but have never received structured training during their medical careers.
He explained that the Education Platform was designed to provide the type of evidence-led learning resource that he believes would have been valuable when he first entered the field.
Dr. Erridge noted that the educational modules focus on delivering clear scientific information while helping clinicians separate evidence-based knowledge from misinformation, ultimately enabling responsible integration of medical cannabis into clinical practice.
Education as the Foundation for Responsible Access
Curaleaf International CEO Juan Martinez emphasized that education represents one of the most important drivers of responsible access to medical cannabis.
He explained that healthcare professionals equipped with reliable, evidence-based training are better positioned to make informed prescribing decisions and support appropriate patient care.
According to Martinez, improving clinician confidence contributes not only to better healthcare delivery but also to building greater trust among patients, healthcare providers, regulators, and the wider medical community.
He suggested that sustainable long-term growth within the medical cannabis sector depends on expanding access to high-quality education alongside continued clinical research.
The Future of Medical Cannabis Education
The launch of the Curaleaf Education Platform reflects a broader shift within healthcare toward improving professional education as medical cannabis becomes a more established therapeutic option.
As clinical evidence continues to evolve and patient access expands, healthcare professionals will increasingly require reliable educational resources to remain current with scientific developments and regulatory expectations.
Digital learning platforms offer an accessible solution by allowing clinicians to study at their own pace while earning accredited professional development credits.
By combining scientific research, real-world patient data, structured clinical guidance, and CPD accreditation, Curaleaf aims to support a more informed healthcare workforce capable of making evidence-based decisions regarding cannabis-based medicines.
As the UK medical cannabis landscape continues to mature, initiatives focused on clinician education are expected to play an increasingly important role in improving patient care, supporting responsible prescribing practices, and fostering greater confidence throughout the healthcare system.
Source link: https://www.businesswire.com/
